Angiostatin and anti-angiogenic therapy in human disease.
Angiostatin and anti-angiogenic therapy in human disease.
复制标题
DOI：
10.1210/rp.59.1.73
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
M. Wahl;T. Moser;S. Pizzo
中科院分区：
文献类型：
--
作者：
M. Wahl;T. Moser;S. Pizzo
许多疾病都以血管化的质量和/或数量异常为特征。癌细胞在新血管形成过程中引发新毛细血管的生长，这一过程称为血管生成。在糖尿病患者中，各种组织中的病理性血管生成是许多常见并发症的临床特征。因此，糖尿病癌症患者在设计抗血管生成治疗时需要特别考虑和额外小心，以免产生不良副作用。一些在体外、动物模型或早期临床试验中看起来很有希望的治疗方案可能对糖尿病患者是禁忌的。本章将回顾糖尿病的常见并发症，重点是血管生成病理学。最近与抗血管生成肽血管抑制素的作用机制和特异性基础相关的研究将成为焦点。目的是阐明需要对血管抑制素和其他抗血管生成剂以及影响其活性的微环境条件进行更多研究的领域，以便为糖尿病癌症患者开发改进的治疗策略。
Many diseases have abnormal quality and/or quantity of vascularization as a characteristic feature. Cancer cells elicit the growth of new capillaries during neovascularization in a process termed angiogenesis. In diabetics, pathologic angiogenesis in various tissues is a clinical feature of many common complications. Therefore, the diabetic cancer patient warrants special consideration and extra care in the design of anti-angiogenic treatments without adverse side effects. Some treatment regimens that look promising in vitro, in animal models, or in early clinical trials may be contra-indicated for diabetics. This chapter will review the common complications of diabetes, with emphasis on the angiogenic pathology. Recent research related to the mechanism of action and basis for specificity of the anti-angiogenic peptide, angiostatin, will be the focus. The aim is to shed light on areas in which more research is needed with respect to angiostatin and other anti-angiogenic agents and the microenvironmental conditions that affect their activities, in order to develop improved therapeutic strategies for diabetic cancer patients.